CN103058935B - 一种嘧啶类化合物及其制备方法和用途 - Google Patents
一种嘧啶类化合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN103058935B CN103058935B CN201310013707.1A CN201310013707A CN103058935B CN 103058935 B CN103058935 B CN 103058935B CN 201310013707 A CN201310013707 A CN 201310013707A CN 103058935 B CN103058935 B CN 103058935B
- Authority
- CN
- China
- Prior art keywords
- formoxime
- chloropyrimide
- dmso
- compound
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- -1 Pyrimidine compound Chemical class 0.000 title claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 22
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 9
- 150000003230 pyrimidines Chemical class 0.000 claims description 9
- 241000700584 Simplexvirus Species 0.000 claims description 7
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 208000037797 influenza A Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 2
- 230000003602 anti-herpes Effects 0.000 claims description 2
- 208000029565 malignant colon neoplasm Diseases 0.000 claims description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 2
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 230000009876 antimalignant effect Effects 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 206010009944 Colon cancer Diseases 0.000 abstract description 5
- 210000004881 tumor cell Anatomy 0.000 abstract description 3
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 35
- 238000005481 NMR spectroscopy Methods 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000002994 raw material Substances 0.000 description 13
- 230000003044 adaptive effect Effects 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 238000010189 synthetic method Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000002585 base Substances 0.000 description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 6
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 101100391174 Dictyostelium discoideum forC gene Proteins 0.000 description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940100050 virazole Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 0 CC(C)c1c(*)c(*)c(*)c(*)c1* Chemical compound CC(C)c1c(*)c(*)c(*)c(*)c1* 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- BTBOAWKKGBLPTH-PJQLUOCWSA-N O/N=C/c(c(NCc1ccc[o]1)ncn1)c1Cl Chemical compound O/N=C/c(c(NCc1ccc[o]1)ncn1)c1Cl BTBOAWKKGBLPTH-PJQLUOCWSA-N 0.000 description 1
- INJVMJVGAXFFPN-REZTVBANSA-N O/N=C/c(c(NCc1ccccc1)ncn1)c1Cl Chemical compound O/N=C/c(c(NCc1ccccc1)ncn1)c1Cl INJVMJVGAXFFPN-REZTVBANSA-N 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000011951 anti-virus test Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- CUBCNYWQJHBXIY-UHFFFAOYSA-N benzoic acid;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1O CUBCNYWQJHBXIY-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002624 bretylium tosilate Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- HCPOCMMGKBZWSJ-UHFFFAOYSA-N ethyl 3-hydrazinyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NN HCPOCMMGKBZWSJ-UHFFFAOYSA-N 0.000 description 1
- 229950004385 flunamine Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种嘧啶类化合物或其药学上可接受的盐。本发明还提供了该化合物的制备方法和用途。本发明提供的嘧啶类化合物,对肿瘤细胞和病毒均具有抑制作用,尤其抗结肠癌、流感和疱疹病毒效果良好,为临床用药提供了新的选择。
Description
技术领域
本发明涉及一种嘧啶类化合物及其制备方法和用途。
背景技术
癌症(Cancer),亦称恶性肿瘤(Malignant neoplasm),为由控制细胞生长增殖机制失常而引起的疾病。癌细胞除了生长失控外,还会局部侵入周遭正常组织甚至经由体内循环系统或淋巴系统转移到身体其他部分。随着环境污染的日益加剧,全世界的癌症患者数量也与日俱增。
病毒,是由一个核酸分子(DNA或RNA)与蛋白质构成的非细胞形态的营寄生生活的生命体。感染病毒后,主要表现有发热、头痛、全身不适等全身中毒症状及病毒寄主和侵袭组织器官导致炎症损伤而引起的局部症状。病毒感染极易在人体间传播,若控制不当还会产生大范围感染,对人体和社会危害较为严重。
因此,新的抗癌药物、抗病毒药物的研发就具有非常重要的意义。
发明内容
本发明的目的在于提供一种具有良好生物活性的嘧啶类化合物。本发明的另一目的在于提供该类化合物的制备方法和用途。
本发明提供了式1所示的化合物或其药学上可接受的盐,其结构如下:
其中,R选自取代或非取代的C4-10的芳香基或杂环芳香基。
进一步地,R选自取代或非取代的C4-6的芳香基或杂环芳香基;其中,所述杂环芳香基为含O或N杂环芳香基。
进一步地,所述取代的芳香基或杂环芳香基中,取代基选自C1-6的烷基、C1-4的烷氧基、C1-4的氨烷基或卤素。
更进一步地,取代基选自C1-4的烷基、C1-2的烷氧基、C1-2的氨烷基、氨基或卤素。
进一步地,所述化合物为
其中,R1~R5选自C1-6的烷基、C1-4的烷氧基、C1-4的氨烷基、氨基或H。
进一步地,R1~R5选自C1-4的烷基、C1-2的烷氧基、C1-2的氨烷基、氨基或H。
更进一步地,所述烷基为甲基,烷氧基为甲氧基,氨烷基为氨甲基。
优选地,所述化合物为:4-(4-甲氧基苄胺)-5-甲醛肟-6-氯嘧啶、4-(4-甲基苄胺)-5-甲醛肟-6-氯嘧啶、4-(2-甲氧基苄胺)-5-甲醛肟-6-氯嘧啶、4-(3-甲氧基苄胺)-5-甲醛肟-6-氯嘧啶、4-(4-氨甲基苄胺)-5-甲醛肟-6-氯嘧啶、4-苄胺-5-甲醛肟-6-氯嘧啶、或4-(4-氨基苄胺)-5-甲醛肟-6-氯嘧啶。
进一步优选地,所述化合物为4-(4-甲氧基苄胺)-5-甲醛肟-6-氯嘧啶或4-苄胺-5-甲醛肟-6-氯嘧啶。
本发明还提供了上述式1化合物的制备方法,它包括如下操作步骤:
(1)取4,6-二氯嘧啶-5甲醛,与羟氨类化合物反应生成4,6-二氯嘧啶-5甲醛肟
(2)将4,6-二氯嘧啶-5甲醛肟与式3化合物进行反应,生成式1化合物
其中,R选自取代或非取代的C4-10的芳香基或杂环芳香基。若需要制备式2化合物,进一步选择相应的R基团即可。
本发明还提供了上述化合物或其药学上可接受的盐在制备抗肿瘤或抗病毒的药物中的用途。
进一步地,所述肿瘤为结肠恶性肿瘤。
进一步地,所述病毒为单纯疱疹病毒或A型流感病毒。
更进一步地,所述A型流感病毒为H3N2,所述单纯疱疹病毒为I型。
本发明所述“药学上可接受的盐”包括通式1或2化合物与对活生物体无毒性的盐,包含有本发明化合物与盐酸、氢溴酸、硝酸、硫酸、磷酸、柠檬酸、苹果酸、甲酸、马来酸、乙酸、丙二酸、双羟萘酸、1,5-萘二磺酸、环己基氨基磺酸、水杨酸、己二酸、戊二酸、香草酸、草酰乙酸、抗坏血酸、乳酸、富马酸、琥珀酸、酒石酸、甲磺酸或对甲苯磺酸等形成的盐类,或,本发明化合物与碱形成的含钠、钾、镁、锌或铁等的盐类,但并不局限于此。
本发明提供的嘧啶类化合物,对肿瘤细胞和病毒均具有抑制作用,尤其抗结肠癌、流感和疱疹病毒效果良好,为临床用药提供了新的选择。
具体实施方式
实施例1 4,6-二氯嘧啶-5甲醛肟
将1.8g4,6-二氯嘧啶-5甲醛溶于20ml冰乙酸,然后滴入40ml盐酸羟胺乙醇溶液(1.4g),常温反应15小时。溶液旋干后,将产物用20ml乙醚溶解,滤去沉淀后,用饱和NaHCO3和水洗有机相,最后用无水硫酸钠干燥有机相,旋干得到白色产物4,6-二氯嘧啶-5甲醛肟(1.8g,84%产率)。1HNMR(400MHz;DMSO-d6):δ=8.19(s,1H),8.91(s,1H),12.27(s,1H).13C NMR(600MHz;DMSO-d6)δ=113.63,142.03,149.50,154.25.Anal.Calcd forC5H3Cl2N3O:C,31.28;H,1.57;N,21.89.Found C,31.44;H,1.46;N,22.17.
实施例2 4-(4-甲氧基苄胺)-5-甲醛肟-6-氯嘧啶(J0)
将1.5g化合物4,6-二氯嘧啶-5甲醛肟,溶解在45ml干燥THF中。向此溶液中加入对甲氧基苄胺(6mL,2M),混合溶液在室温反应10分钟后加热到70℃,继续反应1小半时。反应终止时间以TLC监测原料消耗为准(展开剂:DCM,Rf=0.2)。待反应停止后,向溶液中加入100mL水以终止反应并用DCM稀释,有机相再用稀盐酸和水各洗涤一次,有机相用无水硫酸钠干燥后旋干得到泡沫状产物,柱层析分离(洗脱剂:DCM)得到无色产物4-(4-甲氧基苄胺)5-甲醛肟-6-氯嘧啶(2g,80%)。1H NMR(400MHz,d6-DMSO)δ3.74(s,3H,OMe),4.71(d,J=5.6Hz,2H,CH2),6.92-7.27(dd,J1=8.6Hz,J2=8.5Hz,4H,C6 H 4-OMe),8.35(s,1H,NCH),8.48(s,1H,CH),8.79(s,1H,NH),11.91(s,1H,OH);13C NMR(100MHz,d6-DMSO)δ44.31,55.55,105.64,114.50,129.33,130.49,145.75,157.22,158.26;UV(MeOH):λmax(ε):223(26202);267(9207);316(5118);HRMS(EI)calcd for C21H14ClN5O3:292.0727,found:292.0729.结构式如下:
实施例3 4-(4-甲基苄胺)-5-甲醛肟-6-氯嘧啶(J1)
按照J0的合成方法,适应性改变反应原料后,合成J1:778mg,Yield:94%.
1H NMR(400MHz,d6-DMSO)δ3.74(s,3H,OMe),4.71(d,J=5.6Hz,2H,CH2),6.92-7.27(dd,J1=8.6Hz,J2=8.5Hz,4H,C6 H 4-OMe),8.35(s,1H,NCH),8.48(s,1H,CH),8.79(s,1H,NH),11.91(s,1H,OH);13C NMR(100MHz,d6-DMSO)δ44.31,55.55,105.64,114.50,129.33,130.49,145.75,157.22,158.26;UV(MeOH):λmax(ε):221(29259);266(9479);316(6169);HRMS(EI)calcd for C21H14ClN5O3:276.0778,found:276.0780.结构式如下:
实施例4 4-(4-叔丁基苄胺)-5-甲醛肟-6-氯嘧啶(J2)
按照J0的合成方法,适应性改变反应原料后,合成J2:830mg,Yield:87%.
1H NMR(400MHz,d6-DMSO)δ1.27(s,9H,CMe3),4.76(d,J=5.7Hz,2H,CH2),7.25-7.38(dd,J1=8.2Hz,J2=8.2Hz,4H,C6H4),8.34(s,1H,NCH),8.50(s,1H,CH),8.87(s,1H,NH),11.94(s,1H,OH);13C NMR(100MHz,d6-DMSO)δ31.59,34.67,44.41,105.71,125.83,127.57,135.65,145.76,150.15,157.22,158.28,159.51;UV(MeOH):λmax(ε):221(29344);265(9555);316(6103);HRMS(EI)calcd for C21H14ClN5O3:318.1247,found:318.1253.结构式如下:
实施例5 4-(2-甲氧基苄胺)-5-甲醛肟-6-氯嘧啶(J3)
按照J0的合成方法,适应性改变反应原料后,合成J3:815mg,Yield:93%.
1H NMR(400MHz,d6-DMSO)δ3.85(s,3H,OMe),4.72(d,J=5.7Hz,2H,CH2),6.91(t,J=7.4Hz,1H),7.03(d,J=8.2Hz,1H),7.33–7.19(m,2H),8.32(s,1H,NCH),8.48(s,1H,CH),8.90(s,1H,NH),11.92(s,1H,OH);13C NMR(100MHz,d6-DMSO)δ55.85,105.70,111.33,120.76,126.03,129.00,129.30,145.72,157.18,157.64,158.26,159.44;UV(MeOH):λmax(ε):220(28018);269(10285);317(5907);HRMS(EI)calcd for C21H14ClN5O3:292.0727,found:292.0731.结构式如下:
实施例6 4-(3-甲氧基苄胺)-5-甲醛肟-6-氯嘧啶(J4)
按照J0的合成方法,适应性改变反应原料后,合成J4:832mg,Yield:95%.
1H NMR(400MHz,d6-DMSO)δ3.74(s,3H,OMe),4.77(d,J=5.7Hz,2H,CH2),6.93–6.82(m,3H),7.27(t,J=8.1Hz,1H),8.34(s,1H,NCH),8.50(s,1H,CH),8.86(s,1H,NH),11.94(s,1H,OH);13C NMR(100MHz,d6-DMSO)δ44.73,55.48,105.76,113.08,113.58,119.85,130.21,140.28,145.76,157.21,158.28,159.52,159.93;UV(MeOH):λmax(ε):221(26401);268(8205);315(4903);HRMS(EI)calcd for C21H14ClN5O3::292.0727,found:292.0724.结构式如下:
实施例7 4-(4-氯苄胺)-5-甲醛肟-6-氯嘧啶(J5)
按照J0的合成方法,适应性改变反应原料后,合成J5:844mg,Yield:95%.
1H NMR(400MHz,d6-DMSO)δ4.78(d,J=5.8Hz,2H,CH2),7.34-7.42(dd,J1=23.2Hz,J2=8.5Hz,4H,C6 H 4-OMe),8.33(s,1H,NCH),8.49(s,1H,CH),8.89(s,1H,NH),11.94(s,1H,OH);13C NMR(100MHz,d6-DMSO)δ44.03,105.95,128.99,129.63,132.24,137.91,145.69,157.19,158.28,159.55;UV(MeOH):λmax(ε):221(23089);265(7250);314(4711);HRMS(EI)calcd forC21H14ClN5O3:296.0232,found:296.0236.结构式如下:
实施例8 4-(4-溴苄胺)-5-甲醛肟-6-氯嘧啶(J6)
按照J0的合成方法,适应性改变反应原料后,合成J6:966mg,Yield:95%.
1H NMR(400MHz,d6-DMSO)δ4.77(d,J=5.8Hz,2H,CH2),7.28-7.55(dd,J1=8.3Hz,J2=8.4Hz,4H,C6 H 4-OMe),8.33(s,1H,NCH),8.49(s,1H,CH),8.89(s,1H,NH),11.94(s,1H,OH);13C NMR(100MHz,d6-DMSO)δ44.10,105.88,120.72,129.98,131.91,138.34,145.69,157.19,158.27,159.52;UV(MeOH):λmax(ε):221(30025);265(9603);314(6067);HRMS(EI)calcd forC21H14ClN5O3:339.9727,found:339.9721.结构式如下:
实施例9 4-(4-氟苄胺)-5-甲醛肟-6-氯嘧啶(J7)
按照J0的合成方法,适应性改变反应原料后,合成J7:798mg,Yield:95%.
1H NMR(400MHz,d6-DMSO)δ4.78(d,J=5.8Hz,2H,CH2),7.18(t,J=8.8Hz,2H),7.36-7.40(dd,J1=8.5Hz,J2=5.6Hz,2H),8.34(s,1H,NCH),8.49(s,1H,CH),8.87(s,1H,NH),11.93(s,1H,OH);13C NMR(100MHz,d6-DMSO)δ44.10,105.88,120.72,129.98,131.91,138.34,145.69,157.19,158.27,159.52;UV(MeOH):λmax(ε):221(23380);264(8626);315(5717);HRMS(EI)calcdfor C21H14ClN5O3:280.0527,found:280.0529.结构式如下:
实施例10 4-(4-氨甲基苄胺)-5-甲醛肟-6-氯嘧啶(J8)
按照J0的合成方法,适应性改变反应原料后,合成J8:724mg,Yield:83%.
1H NMR(400MHz,d6-DMSO)δ3.74(s,3H,OMe),4.71(d,J=5.6Hz,2H,CH2),6.92-7.27(dd,J1=8.6Hz,J2=8.5Hz,4H,C6 H 4-OMe),8.35(s,1H,NCH),8.48(s,1H,CH),8.79(s,1H,NH),11.91(s,1H,OH);13C NMR(100MHz,d6-DMSO)δ44.31,55.55,105.64,114.50,129.33,130.49,145.75,157.22,158.26;UV(MeOH):λmax(ε):263(13380);HRMS(EI)calcd forC21H14ClN5O3:291.0887,found:291.0882.结构式如下:
实施例11 4-苯胺-5-甲醛肟-6-氯嘧啶(J9)
按照J0的合成方法,适应性改变反应原料后,合成J9:670mg,90%。1H NMR(400MHz,d6-DMSO)δ7.18(t,J=7.4Hz,1H),7.42(t,J=7.9Hz,2H),7.65(d,J=8.0Hz,2H),8.44(s,1H,NCH),8.56(s,1H,CH),10.69(s,1H,NH),12.25(s,1H,OH);13C NMR(100MHz,d6-DMSO)δ106.84,122.24,124.97,129.46,138.35,145.41,156.93,157.59,158.74;UV(MeOH):λmax(ε):203(53642);225(36642);HRMS(EI)calcd for C21H14ClN5O3:248.0465,found:248.0470.结构式如下:
实施例12 4-苄胺-5-甲醛肟-6-氯嘧啶(J11)
按照J0的合成方法,适应性改变反应原料后,合成J11:715mg,Yield:91%.
1H NMR(400MHz,d6-DMSO)δ4.80(d,J=5.7Hz,2H,CH2),7.23–7.41(m,5H,C6H5),,8.34(s,1H,NCH),8.50(s,1H,CH),8.89(s,1H,NH),11.94(s,1H,OH);13C NMR(100MHz,d6-DMSO)δ44.74,105.76,127.73,127.77,129.09,138.72,145.76,157.22,158.28,159.55;UV(MeOH):λmax(ε):220(36799);264(12239);315(8419);HRMS(EI)calcd for C21H14ClN5O3:262.0621,found:262.0629.结构式如下:
实施例13 4-(4-氨基苄胺)-5-甲醛肟-6-氯嘧啶(J12)
按照J0的合成方法,适应性改变反应原料后,合成J12:590mg,Yield:71%.
1H NMR(400MHz,d6-DMSO)δ4.56(d,J=5.2,2H,CH2),5.08(s,2H,NH2),6.53-7.03(dd,J1=8.4Hz,J2=8.4Hz,4H,C6 H 4-NH2),8.34(s,1H,NCH),8.47(s,1H,CH),8.63(t,J=5.1,1H,NH),11.92(s,1H,OH);13C NMR(100MHz,d6-DMSO)δ44.41,104.95,114.19,124.85,128.68,145.27,147.63,156.72,157.71,158.65;UV(MeOH):λmax(ε):221(24171);315(5398);HRMS(EI)calcd for C21H14ClN5O3:277.0730,found:277.0738.结构式如下:
实施例14 4-糠胺-5-甲醛肟-6-氯嘧啶(J18)
按照J0的合成方法,适应性改变反应原料后,合成J18:600mg,Yield:72%.
1H NMR(400MHz,d6-DMSO)δ4.80(d,J=5.5Hz,2H,CH2),6.37–6.44(m,2H,C2 H 2-C2HO),7.63(d,J=1.0,1H,CHO-C3H2),8.37(s,1H,NCH),8.48(s,1H,CH),8.80(t,J=5.4Hz,1H,NH),12.01(s,1H,OH);13C NMR(100MHz,d6-DMSO)δ37.52,105.38,107.59,110.55,142.70,145.13,151.00,156.62,157.78,158.78;UV(MeOH):λmax(ε):220(25023);264(7427);312(6111);HRMS(EI)calcd for C21H14ClN5O3:252.0414,found:252.0414.结构式如下:
以下通过试验例具体说明本发明的有益效果。
试验例1 本发明化合物抗肿瘤活性实验
将各样品用DMSO配成母液,然后溶于培养液,检测时用培养液稀释成6个梯度(1μM-100μM)的浓度。结肠癌细胞种于96孔培养板,培育24小时后按不同稀释浓度分别加入样品,加药72小时后用MTT法检测药物的IC50。其结果见表1.
表1
由表1可知,本发明化合物具有一定的抗结肠癌作用,其中,以J0、J11化合物活性最佳。
试验例2 本发明化合物抗病毒试验
(一)抗流感病毒活性筛选
测试原理:以MDCK(狗肾)细胞为病毒宿主,测定样品抑制病毒引起细胞病变程度(CPE)。
测试材料和方法:
1.病毒株:流感病毒A H3N2在鸡胚尿囊腔内培养传代,-80℃保存。
2.样品处理:样品溶于DMSO配成适宜初始浓度,再用培养液作3倍稀释,各8个稀释度。
3.阳性对照药:病毒唑(RBV)
4.测试方法:MDCK细胞接种96孔培养板,置5%CO2,37℃培养24小时。MDCK细胞加入流感病毒,37℃吸附2小时后倾去病毒液,分别加入不同稀释度药物的维持液。同时设病毒对照和细胞对照,37℃培养待病毒对照组病变程度(CPE)达4+时观察各组细胞病变程度(CPE)(约37小时),计算各样品抗流感病毒半数抑制浓度(IC50)。测试结果见表2。
(二)抗疱疹病毒I型(HSV-I)活性筛选
测试原理:以Vero(非洲绿猴肾)细胞为病毒宿主,测定样品抑制疱疹病毒I型引起Vero细胞病变程度。
测试材料和方法:
1.病毒株:HSV-I,VR733
2.样品处理:样品临用前DMSO配成母液,检测时用培养液稀释成一定浓度后再作3倍稀释,共8个稀释度。
3.阳性对照药:病毒唑(RBV)
4.测试方法:Vero细胞种96孔培养板,24小时后感染疱疹病毒I型10-4,吸附2小时,弃病毒液,加入含有不同稀释度样品及阳性对照药的维持液,同时设细胞对照孔和病毒对照孔,待病毒对照组病变程度(CPE)达4+时观察各组细胞病变程度(CPE),用Reed-Muench法分别计算样品对疱疹病毒I型的半数抑制浓度(IC50)测试结果见表2。
表2
由上述结果可知,本发明化合物对流感病毒、疱疹病毒均有良好的抑制作用,其中,以J0、J11化合物活性最佳。
综上所述,本发明提供的各化合物,对肿瘤细胞和病毒均具有抑制作用,尤其抗结肠癌、流感和疱疹病毒效果良好,为临床用药提供了新的选择。
Claims (7)
1.式2所示的嘧啶类化合物或其药学上可接受的盐,其结构如下:
其中,R1~R5选自C1-6的烷基、C1-4的烷氧基、C1-4的氨烷基、氨基或H。
2.根据权利要求1所述的嘧啶类化合物或其药学上可接受的盐,其特征在于:R1~R5选自C1-2的烷基、C1-2的烷氧基、C1-2的氨烷基、氨基或H。
3.根据权利要求2所述的嘧啶类化合物或其药学上可接受的盐,其特征在于:所述烷基为甲基,烷氧基为甲氧基,氨烷基为氨甲基。
4.根据权利要求1-3任意一项所述的嘧啶类化合物或其药学上可接受的盐,其特征在于:所述化合物为:
4-(4-甲氧基苄胺)-5-甲醛肟-6-氯嘧啶、或
4-苄胺-5-甲醛肟-6-氯嘧啶
。
5.权利要求1所述式2化合物的制备方法,其特征在于:它包括如下操作步骤:
(1)取4,6-二氯嘧啶-5甲醛,与羟氨类化合物反应生成4,6-二氯嘧啶-5甲醛肟
(2)将4,6-二氯嘧啶-5甲醛肟与式3化合物进行反应,生成式2化合物
其中,R选自
R1~R5选自C1-6的烷基、C1-4的烷氧基、C1-4的氨烷基、氨基或H。
6.权利要求1-4任意一项所述嘧啶类化合物或其药学上可接受的盐在制备抗结肠恶性肿瘤或抗单纯疱疹病毒或A型流感病毒的药物中的用途。
7.根据权利要求6所述的用途,其特征在于:所述A型流感病毒为H3N2,所述单纯疱疹病毒为I型。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310013707.1A CN103058935B (zh) | 2013-01-15 | 2013-01-15 | 一种嘧啶类化合物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310013707.1A CN103058935B (zh) | 2013-01-15 | 2013-01-15 | 一种嘧啶类化合物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103058935A CN103058935A (zh) | 2013-04-24 |
CN103058935B true CN103058935B (zh) | 2015-05-06 |
Family
ID=48101869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310013707.1A Expired - Fee Related CN103058935B (zh) | 2013-01-15 | 2013-01-15 | 一种嘧啶类化合物及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103058935B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015161479A1 (zh) * | 2014-04-24 | 2015-10-29 | 四川大学 | 一种嘧啶类化合物的抗宫颈癌用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09301958A (ja) * | 1996-05-09 | 1997-11-25 | Nippon Shoji Kk | 新規ピリミジン化合物及び抗ロタウイルス剤 |
JPH10212235A (ja) * | 1997-01-29 | 1998-08-11 | Nippon Shoji Kk | 抗腫瘍剤 |
GB0022438D0 (en) * | 2000-09-13 | 2000-11-01 | Novartis Ag | Organic Compounds |
GB0108606D0 (en) * | 2001-04-05 | 2001-05-23 | Novartis Ag | Organic compounds |
WO2007081630A2 (en) * | 2005-12-21 | 2007-07-19 | Janssen Pharmaceutica, N.V. | Substituted pyrimidinyl kinase inhibitors |
-
2013
- 2013-01-15 CN CN201310013707.1A patent/CN103058935B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN103058935A (zh) | 2013-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7031002B2 (ja) | ピリジノイミダゾール系化合物の結晶型、塩型及びその製造方法 | |
CN101679421A (zh) | 新咪唑并[4,5-b]吡啶-7-甲酰胺704 | |
JP2010522157A (ja) | 潜在的制癌剤としての新規アントラニル酸誘導体及びその調製方法 | |
Bera et al. | Discovery of mixed type thymidine phosphorylase inhibitors endowed with antiangiogenic properties: Synthesis, pharmacological evaluation and molecular docking study of 2-thioxo-pyrazolo [1, 5-a][1, 3, 5] triazin-4-ones. Part II | |
CN106432247A (zh) | 含有腙键的嘧啶并三氮唑类化合物、制备方法及其应用 | |
CN104529895B (zh) | 一种取代含氮杂环化合物的合成方法 | |
CN107311905B (zh) | 一类诺蒎酮缩氨基硫脲衍生物及其制备方法和应用 | |
CN103880822B (zh) | 含1,2,3-三氮唑的2,4,6-三取代的嘧啶类化合物、制备方法及其应用 | |
CN105175414A (zh) | 咪唑[4,5-b]吡啶巯乙酰胺类衍生物及其制备方法与应用 | |
CN103058935B (zh) | 一种嘧啶类化合物及其制备方法和用途 | |
KR102604939B1 (ko) | 항바이러스제 및 그 용도 | |
CN101638391B (zh) | 2-[(取代苯氨基)羰基甲硫基]-6-(2,6-二氯苄基)-3h-嘧啶-4-酮类衍生物及其制备方法与应用 | |
JP7101781B2 (ja) | Akt阻害剤としての塩形態及びその結晶形態 | |
CN111518104A (zh) | 一种含硫脲嘧啶的1,2,4-三氮唑并[1,5-a]嘧啶类化合物及其制备方法和应用 | |
CN104586842B (zh) | 一种抗癌活性吲哚衍生物、合成方法及其用途 | |
CN106397407B (zh) | 抗肿瘤药物azd9291衍生物的制备方法 | |
CN103626769A (zh) | 取代巯基六元芳杂环并咪唑类衍生物及其制备方法与应用 | |
CN104817539B (zh) | 2‑苯氧基喹喔啉衍生物及其医药用途 | |
CN103351346A (zh) | 盐酸苯达莫司汀杂质hp1的制备方法 | |
CN103864642A (zh) | 大黄酸衍生物及其合成方法和用途 | |
CN106588690B (zh) | 毛鸡骨草甲素Abrusamide的制备方法 | |
Montgomery et al. | Deaza Analogs of 6-Mercaptopurine1 | |
CN108503593B (zh) | 2-氨基嘧啶类化合物及其应用 | |
CN113754599B (zh) | 一种吡嗪酰胺化合物及其制备方法 | |
CN104876935B (zh) | 2‑氨基吡咯并[1,2‑f][1,2,4]三嗪类化合物、合成方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150506 |
|
CF01 | Termination of patent right due to non-payment of annual fee |